Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
AP5KcJ0106JR5w5d